Name: AS 602801
Price: 223.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Kinases represent one of the most popular and promising target class in drug discovery. Success in finding new therapeutics will depend on the validation of the kinase chosen with respect to the disease of interest, and on the ability of chemists to design and synthesize inhibitors. AS602801 is a potent and selective JNK inhibitor with therapeutic potential inMS and fibrosis.
    In vitro: AS602801 blocked T-lymphocyte proliferation and induced apoptosis. In RRMS CD4t and CD8t cells, AS602801 induced apoptosis genes and expression of surface markers, while in RRMS CD11bt cells it induced expression of innate immunity receptors and co-stimulatory molecules [1].
    In vivo: AS602801, the best JNK inhibitors identified so far, were currently evaluated in preclinical studies, based on preliminary promising results in animal model of auto-immune diseases and neuronal apoptosis [1].
    Clinical trial: Recently, a phase IIa proof of concept study of the pan-JNK inhibitor bentamapimod (PGL5001, AS602801) for the treatment of inflammatory endometriosis had been terminated.
- Properties
  - Alternative Name
    
    Bentamapimod;AS602801;AS-602801; 2-(benzo[d]thiazol-2-yl)-2-(2-((4-(morpholinomethyl)benzyl)oxy)pyrimidin-4-yl)acetonitrile
    
    CAS Number
    
    848344-36-5
    
    Molecular Formula
    
    C25H23N5O2S
    
    Molecular Weight
    
    457.55
    
    Appearance
    
    A solid
    
    Purity
    
    99.14%
    
    Solubility
    
    insoluble in H2O; insoluble in EtOH; ≥11.45 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

AS 602801

AS 602801

Background

We Also Recommend

ASC-J9

Ascomycin(FK 520)

Asenapine hydrochloride